FSD Pharma

FSD Pharma lands at 40 on the CIN composite, a Neutral outcome with conviction of 3/5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 49 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

The observable inputs tell a straightforward story: reported revenue growth of -7.4 percent year over year, an operating margin of 0.0 percent, a jurisdictional posture reading of 50. Every figure is auditable in the accompanying pillar table. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets FSD Pharma be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.

Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 49. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.